Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03112694 · ClinicalTrials.gov registry record
Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors
A clinical trial, sponsored by Ipsen.
- Completed
- Registry status
- 93
- Enrollment target
NCT03112694: Completed study, sponsored by Ipsen.
NCT03112694 is a clinical trial that has completed, run by Ipsen. The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03112694 has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- 93 participants
- Enrollment target
Study Summary
The purpose of this study is to understand how people with neuroendocrine tumors respond to treatment with lanreotide after having received treatment with octreotide.
Primary Outcome
Evaluated as responsive disease (i.e., complete response, partial response), stable disease or progressive disease at the last tumor assessment while on treatment with lanreotide (based on tumor imaging, symptoms, biomarker(s) and/or clinical judgement)
Interventions
- OTHER Data collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2017-04-04 |
| Est. Completion | 2017-11-02 |
What the finished NCT03112694 record still lists
NCT03112694 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 93 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Data collection is the first listed.
NCT03112694 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03112694 about?
NCT03112694 is a clinical study titled "Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors". The purpose of this study is to understand how people with neuroendocrine tumors respond to treatment with lanreotide after having received treatment with octreotide.
What is the current status of trial NCT03112694?
This trial is currently completed. The enrollment target is 93 participants. The study started on 2017-04-04. Estimated completion is 2017-11-02.
What interventions are being tested in trial NCT03112694?
The interventions under investigation include: Data collection (OTHER).
Who is sponsoring clinical trial NCT03112694?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI